About NouscomNouscom is a private oncology company developing next generation immunotherapies. Nouscom's proprietary technology platform harnesses the full power of immune response by combining oncolytic viruses specifically targeted to a tumor with viral vectored genetic vaccines based on patient specific neo-antigens.
Co-Founder and CEO of HQ: Riccardo Cortese, PhD, MD
Co-Founder and CEO of Italy: Alfredo Nicosia, PhD
Co-Founder and CSO: Elisa Scarselli, MD
Co-Founder and CTO: Stefano Colloca, MD
Co-Founder and Head of Immunology: Antonella Folgori, PhD
Co-Founder and Senior Director of Regulatory Affairs: Cinzia Traboni, PhD
COO: Marina Udier, PhD
Please click here for Nouscom's science.
11 articles with Nouscom
11/15/2021It was another busy week for clinical trial news. Here’s a look.
9/20/2021With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
3/15/2021It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
2/28/2020Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.
12/12/2019Companies from across the globe provide updates to their business and pipelines.
6/6/2019Companies from across the globe share updates on their pipelines and growth strategies.
Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director
Nouscom announced today that it has appointed John F. McDonald as an independent director to its Board of Directors.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model
Nouscom, an oncology company developing next generation cancer vaccines based on its Exovax platform, today announced preclinical data of its neoantigen-based cancer vaccine in combination with Nektar Therapeutics' NKTR-214, a CD122-biased cytokine agonist which is currently in clinical trials.
The round was led by new investor Abingworth with participation from another new investor, 5AM Ventures, LSP and Versant Ventures.